Navigation Links
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Date:1/7/2008

associated with this disease. Despite currently available medications that treat the conditions that increase the risk of these events, these therapies do not treat the underlying inflammation."

The company provided the following specific update for each of its three Phase 2 clinical trials:

FDG-PET Study

The FDG-PET trial is enrolling approximately 50 patients following a heart attack into a 24 week randomized, double blind, placebo-controlled study. Enrollment is expected to be complete during 2008 and data is expected in the first half of 2009. Endpoints in the study include reduction in plaque inflammation following dosing with VIA-2291 as measured with FDG-PET, as well as assessment of standard biomarker measurements of inflammation. The use of state-of-the art FDG-PET imaging technology provides a new and important methodology for measuring the effect of VIA-2291 in reducing vascular inflammation.

"We are pleased with the progress of our clinical program and the commencement of our third Phase 2 trial to directly demonstrate the impact of VIA-2291 on inflammation in patients with advanced atherosclerotic disease," said Adeoye Olukotun, MD, chief medical officer of VIA. "The data from this study, in combination with our other two trials, is designed to directly assess the safety, mode of action and clinical activity of VIA-2291 to reduce vascular inflammation, and therefore, the risk of major adverse cardiovascular events."

The first patient was randomized to treatment at Massachusetts General Hospital in Boston. Mount Sinai Heart in New York City is also participating in the study.

Carotid Endarterectomy (CEA) Study

VIA has enrolled approximately 40 patients in the CEA study as planned, and is expanding enrollment to gather additional data by taking advantage of additional patients currently in the screening and patient recruitment process. VIA plans to enroll approximately 50 patients and expects to report data
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Since last month,s FBI shutdown ... known as the leading online black market for illegal ... in its offering of drugs and other illegal items.  ... takedowns did succeed in lowering the numbers of drugs ... the markets in August. But some new sites that ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 /PRNewswire/ ... and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced ... insulin, known as BioChaperone Lispro, for treatment in people ... relies on Adocia,s proprietary BioChaperone® technology and is currently ... will develop BioChaperone Lispro with the goal of optimizing ...
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
Breaking Medicine Technology:Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... 23, 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: SNTA) ... commercializing small,molecule drugs to treat severe medical ... from the Phase 2b clinical,trial in metastatic ... STA-4783, will be presented at the annual ...
... - Bentley,Pharmaceuticals, Inc. (NYSE: BNT), a specialty ... abstract sponsored by,the Company has been accepted ... Association 67th Scientific Sessions in Chicago.,The abstract, ... Comparison Study of Intranasal Insulin Spray,(Nasulin(TM)) and ...
Cached Medicine Technology:Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3
(Date:12/20/2014)... December 21, 2014 MissyDress, a distinguished ... all prom lovers. The business has drastically cut prices ... dresses to everyone until Jan. 30, 2015. Many of ... sweetheart dresses, V-neck dresses, lace dresses, and more. , ... not there every day. Whether A-line princess prom dresses ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The print ... Post, with a distribution of approximately 160,000 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with the ladies of CTV’s The ...
(Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... cheaper than more potent drugs like PPIs , , THURSDAY, ... -- the medical name for indigestion -- with run-of-the-mill ... needed, is slightly less costly than starting with the ... patients with new-onset dyspepsia are treated with empirical proton ...
... Year, Legislation Introduced to Fund Lung Cancer ResearchBOSTON, ... hailed Senator Susan Fargo (D-3rd Middlesex), the Senate ... for once again introducing comprehensive legislation that creates ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO )"Now is the time for ...
... Minn., Jan. 15 Rochester Medical,Corporation (Nasdaq: ... have reached a settlement to the litigation which Rochester ... TYCO International (US) Inc.;,TYCO Healthcare Group, L.P.; Novation, LLC; ... Under the terms of the settlement, ...
... Utah, Jan. 15 The annual film festival in Park,City, ... crunches,thanks to Gatorade creating the first ever full-service fitness center, ... both in town for the,festival, are two of the many ... whom will also help raise a "G" or $1,000 for,charity, ...
... 15 On Tuesday, February 3, 2009, legendary folk ... Annual Beyond Beauty Gala to benefit The James E. ... and awareness for Obsessive-Compulsive Disorder (OCD). Hosted by ... will be held at The Union League Club in ...
... Child Health InsuranceTUCSON, Ariz., Jan. 15 ... today provided an update on recent discussions in Washington D.C. ... Obama as well as the recent House of Representatives vote ... under discussion includes aid to state and local governments as ...
Cached Medicine News:Health News:Antacids Are Best First Choice for Indigestion 2Health News:Antacids Are Best First Choice for Indigestion 3Health News:Lung Cancer Alliance Hails Massachusetts State Senator for Taking Lead on Lung Cancer 2Health News:Celebrities Stay Fit at First Ever Full-Service Luxury Gym at Film Festival in Park City, Utah 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 3Health News:Providence Service Corporation Provides Update on Potential Medicaid 2Health News:Providence Service Corporation Provides Update on Potential Medicaid 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: